糖尿病和非酒精性脂肪性肝病相关肝细胞癌的相互关系

张永超; 李威

doi:10.3969/j.issn.1001-5256.2020.10.037

糖尿病和非酒精性脂肪性肝病相关肝细胞癌的相互关系

DOI: 10.3969/j.issn.1001-5256.2020.10.037

张永超,
李威

首都医科大学附属北京地坛医院肿瘤诊治中心

基金项目:

首都卫生发展科研专项(CFH 2020-2-2175)；

详细信息

中图分类号: R575.5； R735.7
计量
- 文章访问数: 463
- HTML全文浏览量: 21
- PDF下载量: 78
- 被引次数: 0
出版历程
- 收稿日期: 2020-02-22
- 出版日期: 2020-10-20

Association between diabetes and nonalcoholic fatty liver disease-related hepatocellular carcinoma

Cancer Center,Beijing Ditan Hospital,Capital Medical University

Research funding:

摘要

摘要:
肝细胞癌(HCC)是常见的恶性肿瘤之一。随着抗病毒治疗的发展和人们生活方式的改变,HCC的主要致病因素正在由病毒性肝炎逐渐转化为非酒精性脂肪性肝病。糖尿病是常见的慢性病之一,目前同时患有糖尿病和非酒精性脂肪性肝病的患者数量越来越多。糖尿病和非酒精性脂肪性肝病具有共同的相互作用机制,并且糖尿病也会促进非酒精性脂肪性肝病进展,以及增加HCC患病风险。现就糖尿病和非酒精性脂肪性肝病与HCC的相互关系进行综述。
- 癌,肝细胞 /
- 非酒精性脂肪性肝病 /
- 糖尿病
Abstract:
Hepatocellular carcinoma( HCC) is one of the most common malignant tumors. With the development of antiviral therapy and the changes in lifestyle,the main pathogenic factor of HCC gradually changes from viral hepatitis to nonalcoholic fatty liver disease. Diabetes mellitus is a common chronic disease,and at present,there is an increasing number of patients with both nonalcoholic fatty liver disease and diabetes. Nonalcoholic fatty liver disease and diabetes share some common mechanisms,and diabetes may promote the progression of nonalcoholic fatty liver disease and increase the risk of HCC. This article reviews the association of diabetes and nonalcoholic fatty liver disease with HCC.
- carcinoma,hepatocellular /
- nonalcoholic fatty liver disease /
- diabetes mellitus

HTML全文

参考文献(45)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med,2019,380(15):1450-1462.

[3] LONARDO A,BYRNE CD,CALDWELL SH,et al. Global epidemiology of nonalcoholic fatty liver disease:Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology,2016,64(4):1388-1389.

[4] EL-SERAG HB,HAMPEL H,JAVADI F. The association between diabetes and hepatocellular carcinoma:A systematic review of epidemiologic evidence[J]. Clin Gastroenterol Hepatol,2006,4(3):369-380.

[5] LOOMBA R,ABRAHAM M,UNALP A,et al. Association between diabetes,family history of diabetes,and risk of nonalcoholic steatohepatitis and fibrosis[J]. Hepatology,2012,56(3):943-951.

[6] YOUNOSSI ZM. Non-alcoholic fatty liver disease-A global public health perspective[J]. J Hepatol,2019,70(3):531-544.

[7] YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al. Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.

[8] KANWAL F,KRAMER JR,MAPAKSHI S,et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease[J].Gastroenterology,2018,155(6):1828-1837,e1822.

[9] YOUNOSSI ZM,OTGONSUREN M,HENRY L,et al. Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to2009[J]. Hepatology,2015,62(6):1723-1730.

[10] YANG JD,LARSON JJ,WATT KD,et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the united states[J]. Clin Gastroenterol Hepatol,2017,15(5):767-775.

[11] FABBRINI E,MOHAMMED BS,MAGKOS F,et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease[J]. Gastroenterology,2008,134(2):424-431.

[12] KANDA T,GOTO T,HIROTSU Y,et al. Molecular mechanisms:Connections between nonalcoholic fatty liver disease,steatohepatitis and hepatocellular carcinoma[J]. Int J Mol Sci,2020,21(4):1525.

[13] BEGRICHE K,MASSART J,ROBIN MA,et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease[J]. Hepatology,2013,58(4):1497-1507.

[14] TANAKA S,MIYANISHI K,KOBUNE M,et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma[J]. J Gastroenterol,2013,48(11):1249-1258.

[15] BAFFY G. Hepatocellular carcinoma in obesity:Finding a needle in the haystack?[J]. Adv Exp Med Biol,2018,1061:63-77.

[16] KIM J,KUNDU M,VIOLLET B,et al. AMPK and m TOR regulate autophagy through direct phosphorylation of Ulk1[J]. Nat Cell Biol,2011,13(2):132-141.

[17] SINGH SS,VATS S,CHIA AY,et al. Dual role of autophagy in hal marks of cancer[J]. Oncogene,2018,37(9):1142-1158.

[18] SCHWABE RF,GRETEN TF. Gut microbiome in HCC-Mechanisms,diagnosis and therapy[J]. J Hepatol,2020,72(2):230-238.

[19] WOLF MJ,ADILI A,PIOTROWITZ K,et al. Metabolic activation of intrahepatic CD8+T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes[J]. Cancer Cell,2014,26(4):549-564.

[20] MA C,KESARWALA AH,EGGERT T,et al. NAFLD causes selective CD4(+)T lymphocyte loss and promotes hepatocarcinogenesis[J]. Nature,2016,531(7593):253-257.

[21] TILG H,MOSCHEN AR,RODEN M. NAFLD and diabetes mellitus[J]. Nat Rev Gastroenterol Hepatol,2017,14(1):32-42.

[22] MARCHESINI G,BRIZI M,MORSELLI-LABATE AM,et al.Association of nonalcoholic fatty liver disease with insulin resistance[J]. Am J Med,1999,107(5):450-455.

[23] MARCHESINI G,BRIZI M,BIANCHI G,et al. Nonalcoholic fatty liver disease:A feature of the metabolic syndrome[J].Diabetes,2001,50(8):1844-1850.

[24] KWOK R,CHOI KC,WONG GL,et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:A prospective cohort study[J]. Gut,2016,65(8):1359-1368.

[25] KOEHLER EM,PLOMPEN EP,SCHOUTEN JN,et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population:The Rotterdam study[J].Hepatology,2016,63(1):138-147.

[26] DOYCHEVA I,CUI J,NGUYEN P,et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE[J]. Aliment Pharmacol Ther,2016,43(1):83-95.

[27] ALEXANDER M,LOOMIS AK,van der LEI J,et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD:Real-world study of 18 million patients in four European cohorts[J]. BMC Med,2019,17(1):95.

[28] HOSSAIN N,AFENDY A,STEPANOVA M,et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2009,7(11):1224-1229.

[29] TALIM M. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients:Response to Targher et al. and Hu et al[J]. Diabetes Care,2007,30(6):e55; author reply e56.

[30] TARGHER G,BERTOLINI L,RODELLA S,et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients[J].Diabetologia,2008,51(3):444-450.

[31] MALAGUARNERA R,BELFIORE A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells[J]. Front Endocrinol(Lausanne),2014,5:10.

[32] GEHMERT S,SADAT S,SONG YH,et al. The anti-apoptotic effect of IGF-1 on tissue resident stem cells is mediated via PI3-kinase dependent secreted frizzled related protein 2(Sfrp2)release[J]. Biochem Biophys Res Commun,2008,371(4):752-755.

[33] LI ZY,YANG Y,MING M,et al. Mitochondrial ROS generation for regulation of autophagic pathways in cancer[J]. Biochem Biophys Res Commun,2011,414(1):5-8.

[34] AHMAD S,KHAN H,SIDDIQUI Z,et al. AGEs,RAGEs and s-RAGE; friend or foe for cancer[J]. Semin Cancer Biol,2018,49:44-55.

[35] BERROU J,FOUGERAY S,VENOT M,et al. Natural killer cell function,an important target for infection and tumor protection,is impaired in type 2 diabetes[J]. PLo S One,2013,8(4):e62418.

[36] FRYDRYCH LM,BIAN G,O’LONE DE,et al. Obesity and type 2 diabetes mellitus drive immune dysfunction,infection development,and sepsis mortality[J]. J Leukoc Biol,2018,104(3):525-534.

[37] DYSON J,JAQUES B,CHATTOPADYHAY D,et al. Hepatocellular cancer:The impact of obesity,type 2 diabetes and a multidisciplinary team[J]. J Hepatol,2014,60(1):110-117.

[38] YASUI K,HASHIMOTO E,KOMORIZONO Y,et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol,2011,9(5):428-433; quiz e50.

[39] MAKAROVA-RUSHER OV,ALTEKRUSE SF,MCNEEL TS,et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States[J]. Cancer,2016,122(11):1757-1765.

[40] YANG JD,AHMED F,MARA KC,et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease[J]. Hepatology,2020,71(3):907-916.

[41] KANWAL F,KRAMER JR,LI L,et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease[J]. Hepatology,2020,71(3):808-819.

[42] IOANNOU GN,GREEN P,LOWY E,et al. Differences in hepatocellular carcinoma risk,predictors and trends over time according to etiology of cirrhosis[J]. PLo S One,2018,13(9):e0204412.

[43] ALEKSANDROVA K,BOEING H,NTHLINGS U,et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer[J]. Hepatology,2014,60(3):858-871.

[44] ASCHA MS,HANOUNEH IA,LOPEZ R,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J]. Hepatology,2010,51(6):1972-1978.

[45] WANG P,KANG D,CAO W,et al. Diabetes mel itus and risk of hepatocellular carcinoma:A systematic review and meta-analysis[J]. Diabetes Metab Res Rev,2012,28(2):109-122.

施引文献

资源附件(0)

访问统计